Clinical Scorecard: AGS Recommends Cautious Approach to Nicotinamide
At a Glance
| Category | Detail |
|---|---|
| Condition | Open-Angle Glaucoma |
| Key Mechanisms | Potential neuroprotective effects through improved mitochondrial function and retinal cell protection. |
| Target Population | Patients with open-angle glaucoma. |
| Care Setting | Clinical trials and ophthalmology practices. |
Key Highlights
- Nicotinamide shows promise as a neuroprotective agent for glaucoma.
- High doses (≥3 g/day) may improve retinal function but raise safety concerns.
- Two cases of drug-induced liver injury reported in clinical trials.
- Nicotinamide is not approved as a glaucoma treatment.
- Further research is needed to establish long-term safety.
Guideline-Based Recommendations
Diagnosis
- Monitor patients for liver function when considering high-dose nicotinamide.
Management
- Caution against high-dose nicotinamide supplementation due to potential risks.
Monitoring & Follow-up
- Regular liver enzyme tests for patients on high doses.
Risks
- Potential for serious liver toxicity and other adverse effects.
Patient & Prescribing Data
Individuals with open-angle glaucoma considering neuroprotective therapies.
Current evidence suggests cautious use of nicotinamide due to safety concerns at higher doses.
Clinical Best Practices
- Educate patients on the potential risks of high-dose nicotinamide.
- Encourage participation in ongoing clinical trials for further insights.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.